Navigation Links
Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses

-- Data Gathered to Assist in Design of Future Trials, Other Programs --

GAITHERSBURG, Md. and LISBON, Portugal, April 26, 2007 /PRNewswire-FirstCall/ -- Iomai Corporation today announced results from a 400-patient, Phase 2 dose-ranging trial of its patch-based vaccine for travelers' diarrhea. The trial was conducted to assess the ability of a range of vaccine doses to generate an immune response against enterotoxigenic E. coli (ETEC) bacteria -- the most common cause of travelers' diarrhea. Researchers found that even at the lowest dose tested, an Iomai patch applied to the arm generated a robust response in more than 95 percent of patients.

The results were presented today by Iomai's Vice President of Clinical Development, Sarah A. Frech, DVM, at the Vaccines for Enteric Diseases 2007 conference in Lisbon, Portugal.

"These results demonstrate the power of Iomai's technology by showing that even a small dose of vaccine, applied to the skin via a patch, is enough to stimulate a robust immune response. The data will help us determine the dose that we will use in our ETEC product," said Gregory M. Glenn, MD, Senior Vice President and Chief Scientific Officer of Iomai. "Iomai's research has shown that, in addition to showing potential benefits against ETEC, the active ingredient in the patch also works as an immune-boosting adjuvant when the patch is used in combination with injected vaccines for influenza. Thus, the results from the dose-ranging ETEC study will also help determine doses for future studies of the Iomai booster patch for seasonal and pandemic influenza."

Travelers' diarrhea sickens between 20 and 50 percent of international travelers to areas where the bacteria is endemic, but no ETEC vaccine is available in the United States. The existing strategy for avoiding travelers' diarrhea -- prophylactic antibiotics -- raises concerns about antibiotic resistance and drug side effects.<
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:7/31/2015)... -- Quietly, sedately, Morocco,s pharmaceutical sector is ... industry is strong, with a well-developed base of local ... One place where the quality of Moroccan ... has quietly become the second largest African exporter of ... Indeed, Moroccan pharma companies have been making inroads as ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... that a new market research report is available in ... Sales Forces , http://www.reportlinker.com/p0154035/Reportlinker-Adds-Reinventing-Pharmaceutical-Sales-Forces.html ... groups and leaner economic times have forced a new ... the previous decade is dead. Faced with the challenge ...
... Oct. 8 Ethicon Endo-Surgery today announced the company ... for the research and design process used in the ... company was recognized among thousands of entries for its ... collaboration with surgeons across the globe to identify specific ...
Cached Medicine Technology:Reportlinker Adds Reinventing Pharmaceutical Sales Forces 2Reportlinker Adds Reinventing Pharmaceutical Sales Forces 3Reportlinker Adds Reinventing Pharmaceutical Sales Forces 4Reportlinker Adds Reinventing Pharmaceutical Sales Forces 5Reportlinker Adds Reinventing Pharmaceutical Sales Forces 6Reportlinker Adds Reinventing Pharmaceutical Sales Forces 7Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM) 2Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM) 3
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:8/1/2015)... Hartford, CT (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil ... 2,175 mile trek of the Appalachian Trail by stepping off Springer Mountain and ... , On July 26th Phil reached Connecticut and was greeted by friends and family. ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
Breaking Medicine News(10 mins):Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... of the disease , , THURSDAY, Jan. 31 (HealthDay News) ... with severe and non-severe asthma, something that could help ... to treatment. , The study, from the Severe Asthma ... asthma and 382 people with mild or moderate asthma. ...
... Corporation (NYSE: HMN ) will release its fourth ... market closes. The,earnings press release will be available shortly ... at http://www.horacemann.com .,Management will host a conference call ... at 10:00 a.m. ET., The call will be ...
... Jan. 31 MedWaves, Inc. announces the receipt,of ... System for general surgery use for the coagulation ... of a microwave generator,and single patient use sterile ... of a product portfolio and indications for use ...
... Jan. 31 Wild Child, an Australian-based,natural health care ... family products containing only natural or nature identical ingredients,announced ... be available in,44 states across the United States through ... and CEO Leanne Preston said the agreement was the,result ...
... University of Oregon scientists say they have identified a ... cells to form into muscles in zebrafish. , Much ... go to lunch, the trigger gene, which is identified ... for muscle formation to begin, a process known as ...
... is a company with a renowned track record ... high throughput technologies. Genomatix algorithms include optimized fast ... complete genome annotation in terms of transcriptome and ... databases in this specific content by a factor ...
Cached Medicine News:Health News:Severe Asthma Unlike Mild Asthma 2Health News:Horace Mann Announces Fourth Quarter Earnings Release and Conference Call 2Health News:MedWaves, Inc. Announces Receipt of United States Food and Drug Administration 510k Clearance to Market Its Patented Microwave Coagulation/Ablation System 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 3Health News:Oregon researchers find trigger gene for muscle development 2
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
... for the quantitative determination of ... or plasma. Two vials, dry ... must be purchased separately for ... reaction. Wavelength: 340 nm. Linearity: ...
Medicine Products: